Why Alnylam Pharmaceuticals, Inc. (ALNY) Stock Fell 25.1% on Oct 29, 2026
What happened
Alnylam Pharmaceuticals reported third-quarter 2026 earnings today, revealing slower-than-expected patient demand growth for its key drug Amvuttra (vutrisiran) in ATTR cardiomyopathy despite sales force expansion, with management noting performance is trending toward the lower end of guidance ranges (investors.alnylam.com). ALNY fell 25.80% from $232.40 to $172.43 on volume of 6.3M shares (7.26x historical average for this time of day).
Alnylam's fourth-quarter 2026 patient start rates and Amvuttra prescription trends, and any management commentary on commercial strategy adjustments or 2027 guidance at the next earnings call.
Other developments that session
Alnylam Pharmaceuticals, Inc. (ALNY) reported Q3 FY2026 EPS of $16.26 vs. $1.66 consensus estimate, beating by 879.5% on 2026-10-29.
Alnylam Pharmaceuticals, Inc. (ALNY) filed a new 10-Q on October 29, 2026.
Frequently asked questions
Why did Alnylam Pharmaceuticals, Inc. (ALNY) stock fall on Oct 29, 2026?
Alnylam Pharmaceuticals reported third-quarter 2026 earnings today, revealing slower-than-expected patient demand growth for its key drug Amvuttra (vutrisiran) in ATTR cardiomyopathy despite sales force expansion, with management noting performance is trending toward the lower end of guidance ranges (investors.alnylam.com). ALNY fell 25.80% from $232.40 to $172.43 on volume of 6.3M shares (7.26x historical average for this time of day).
How much did ALNY stock fall on Oct 29, 2026?
ALNY fell 25.1% during the Oct 29, 2026 trading session.